AR047550A1 - Tratamiento de la depresion y otros trastornos afectivos - Google Patents

Tratamiento de la depresion y otros trastornos afectivos

Info

Publication number
AR047550A1
AR047550A1 ARP040102200A ARP040102200A AR047550A1 AR 047550 A1 AR047550 A1 AR 047550A1 AR P040102200 A ARP040102200 A AR P040102200A AR P040102200 A ARP040102200 A AR P040102200A AR 047550 A1 AR047550 A1 AR 047550A1
Authority
AR
Argentina
Prior art keywords
depression
treatment
affective disorders
gaboxadol
preparation
Prior art date
Application number
ARP040102200A
Other languages
English (en)
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58707228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR047550(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR047550A1 publication Critical patent/AR047550A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP040102200A 2003-06-25 2004-06-23 Tratamiento de la depresion y otros trastornos afectivos AR047550A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300956 2003-06-25
DKPA200400016 2004-01-07

Publications (1)

Publication Number Publication Date
AR047550A1 true AR047550A1 (es) 2006-01-25

Family

ID=58707228

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102200A AR047550A1 (es) 2003-06-25 2004-06-23 Tratamiento de la depresion y otros trastornos afectivos

Country Status (10)

Country Link
KR (1) KR20060025192A (ko)
AR (1) AR047550A1 (ko)
CA (2) CA2529805A1 (ko)
CL (2) CL2004001607A1 (ko)
EA (1) EA200600101A1 (ko)
IS (1) IS8138A (ko)
ME (2) ME00030B (ko)
NO (1) NO20060229L (ko)
RS (1) RS20050911A (ko)
TW (1) TW200509918A (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210110585A (ko) 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
JP2023526439A (ja) 2020-05-20 2023-06-21 セルテゴ セラピューティクス インコーポレイテッド 精神障害の処置のための環重水素化ガボキサドールおよびその使用

Also Published As

Publication number Publication date
ME00030B (me) 2010-06-10
TW200509918A (en) 2005-03-16
IS8138A (is) 2005-11-21
EA200600101A1 (ru) 2006-06-30
CL2004001607A1 (es) 2005-05-27
CA2692334A1 (en) 2004-12-29
NO20060229L (no) 2006-01-16
MEP1908A (xx) 2010-02-10
RS20050911A (en) 2007-08-03
KR20060025192A (ko) 2006-03-20
CA2529805A1 (en) 2004-12-29
CL2010000166A1 (es) 2010-07-02

Similar Documents

Publication Publication Date Title
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
CL2007002635A1 (es) Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion.
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
AR109263A2 (es) Composición que comprende moxidectina
CY1110046T1 (el) Γαβοξαδολη για τη θεραπεια της καταθλιψης και αλλων συναισθηματικων διαταραχων
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
HN2006000971A (es) Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
ES2570856T3 (es) Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
BRPI0508680A (pt) composição de resfriamento natural, composição flavorizante, produto pronto-para-consumo, e, uso de uma composição
CL2020001349A1 (es) Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574)
AR047553A1 (es) La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
CL2008003231A1 (es) Compuestos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo sustituido, inhibidores selectivos de la recaptacion de serotonina; composicion farmaceutica; procedimiento de preparacion; utiles en el tratamiento y/o prevencion de la eyaculacion prematura.
AR056749A1 (es) Formulaciones de dosificacion oral de ibuprofeno organolepticamente aceptables metodos para su preparacion y uso
AR074302A1 (es) Trans-clomifeno para el sindrome metabolico y la diabetes mellitus tipo 2.. metodo
CO6551744A2 (es) Combinación de fármacos con teobromina y su uso en terapia
PA8571901A1 (es) Nueva composicion farmaceutica
AR062784A1 (es) Tratmiento de los vertigos con acetil -l- leucina
AR072425A1 (es) Uso de nifurtimox para el tratamiento de giardiasis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal